BioSpace News Archive

Opinion granted based on positive progression-free survival results from the Phase 3 KEYNOTE-811 trial.

Genetic Technologies Limited advises that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

Lynk Pharmaceuticals Co., Ltd. announced that it has dosed the first patient with atopic dermatitis in a Phase Ib clinical trial of its innovative drug LNK01004.

Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable, locally advanced pancreatic cancer.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU ® (Elacestrant) for the Treatment of Patients with ER+, HER2.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged six months or older.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health

Allied OMS - the country’s only doctor-owned, doctor-led, and doctor-governed management services organization (“MSO”) for oral and maxillofacial surgery (“OMS”) practices, is pleased to announce the appointment of Jonathon Jundt, DDS, MD, FACS, as the company’s Chief Medical Officer (“CMO”).

Tiziana Life Sciences disclosed the receipt of a notice on July 19, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company’s common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450.

YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”) today announced that it plans to release its financial results for the fiscal year ended March 31, 2023 after the U.S. market closes on Wednesday, July 26, 2023.